Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ropivacaine + epinephrine is a combination of two active pharmaceutical ingredients used primarily for local or regional anesthesia in surgical procedures and acute pain management. Ropivacaine is an amide-type local anesthetic that works by blocking voltage-gated sodium channels on nerve fibers, thereby inhibiting the initiation and conduction of nerve impulses, resulting in loss of sensation in the targeted area[1][5][6]. Epinephrine acts as a vasoconstrictor, reducing blood flow at the injection site to potentially decrease systemic absorption of ropivacaine and prolong its local effect; however, clinical evidence suggests that adding epinephrine to ropivacaine does not significantly alter onset time, duration of action, or systemic absorption compared to ropivacaine alone[2][4][5]. The combination may be used for epidural blocks (including labor analgesia), major nerve blocks, and infiltration anesthesia. It is not marketed under a unique brand name but may be compounded for specific clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + epinephrine.